| Name | Title | Contact Details |
|---|
Kerrie Kelly is a multifaceted design studio bringing thoughtful design into everyday life. To work with Kerrie Kelly—whether through residential interiors, corporate partnerships or lifestyle entertainment—is to gain a trusted, industry-savvy partner who bridges the gap between design principles and a life well lived.
Geneva Consulting Group (GCG) is a global network of Management Consulting Firms. We support companies and entrepreneurs across many different countries and industries in important decisions related to strategy, organisation & HR, technology, turnaround & transformation. Whether in Spain, the United States, Indonesia or Argentina, our firms share one common mindset – a ‘can do entrepreneurial vision and attitude. But more so in GCG, our independent minds take pride in providing a fresh perspective, working collaboratively across the world.
American Repertory Ballet (ARB) and; ARBs Princeton Ballet School. New Jerseys leading contemporary ballet company, and the States largest ballet school.
Club Car Wash is a family-owned express car wash company based in Missouri. Founded in 2006 as Tiger Express Wash, it rebranded to Club Car Wash in 2019. The company has rapidly expanded to become one of the largest car wash chains in the Central United States, with over 213 locations and plans for 56 more by 2025. The company specializes in fast and convenient vehicle cleaning services, including exterior washes with advanced technology and various interior cleaning options. They offer membership and subscription plans for regular customers, as well as additional detailing services at select locations. Club Car Wash has grown through both organic development and acquisitions, enhancing its service offerings and geographic reach across multiple states. Their marketing focuses on quality, speed, and customer experience, catering to a diverse customer base that includes daily commuters and fleet operators.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.